Core Points - The company announced a cash dividend distribution of 0.08 yuan per share for the fiscal year 2024, approved at the shareholders' meeting on June 30, 2025 [2][4] - The total cash dividend to be distributed amounts to approximately 60.81 million yuan, based on a total share capital of 760,095,613 shares [4] - The dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the registration date [3] Distribution Plan - The cash dividends will be distributed through the clearing system of the China Securities Depository and Clearing Corporation Limited, with shareholders who have completed designated transactions able to receive their dividends on the payment date [5] - The distribution does not involve the issuance of bonus shares or capital increases [6] - Direct cash dividends will be issued to specific shareholders, including Lao Bai Xing Medical Group Co., Ltd., Zexing Investment Co., Ltd., and Chen Xiulan [9] Taxation Details - For individual shareholders and securities investment funds holding unrestricted circulating shares, no income tax will be withheld at the time of dividend distribution, with the actual cash dividend being 0.08 yuan per share [10] - Tax liabilities will be calculated based on the holding period of the shares, with different tax rates applicable: 20% for holdings of one month or less, 10% for holdings between one month and one year, and no tax for holdings over one year [10] - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, resulting in a net cash dividend of 0.072 yuan per share [11]

Summary of Key Points Core Viewpoint The announcements from Yifeng Pharmacy Chain Co., Ltd. detail the status of its convertible bonds and the management of idle raised funds through financial products, indicating a strategic approach to enhance financial efficiency and shareholder returns. Group 1: Convertible Bond Conversion Status - As of June 30, 2025, a total face value of 163,000 yuan of "Yifeng Convertible Bonds" has been converted into 4,950 shares of the company's A-shares, representing 0.0004% of the total shares before conversion [2][4]. - The remaining unconverted "Yifeng Convertible Bonds" have a face value of 1,797,269,000 yuan, accounting for 99.9909% of the total issuance [2][4]. - During the quarter from April 1, 2025, to June 30, 2025, 2,000 yuan of "Yifeng Convertible Bonds" were converted into 60 shares [2][4]. Group 2: Convertible Bond Issuance Overview - The company issued 17,974,320 convertible bonds with a total face value of 179,743.20 million yuan, approved by the China Securities Regulatory Commission on March 4, 2024 [3]. - The bonds were listed on the Shanghai Stock Exchange on March 27, 2024, and can be converted into shares starting from September 9, 2024 [3]. Group 3: Management of Idle Funds - The company redeemed structured deposits totaling 10,300.00 million yuan and plans to continue investing 11,400.00 million yuan in new financial products [6][8]. - The board approved the use of up to 30,000.00 million yuan of idle raised funds for financial investments, ensuring that it does not affect the normal operation of investment projects [6][10]. - The investment strategy aims to enhance the efficiency of idle funds and increase company returns without impacting daily operations [13].

Core Viewpoint - The credit rating for Yifeng Pharmacy's convertible bonds remains stable at "AA," with no changes from the previous rating [1]. Group 1 - The previous rating for the convertible bonds was "AA," and the issuer's rating was also "AA," with a stable outlook [1]. - The current rating results for both the issuer and the convertible bonds are unchanged from the last assessment [1]. - The credit rating agency, United Credit Ratings Co., conducted a comprehensive analysis of the company's operational status and industry conditions for this tracking rating [1]. Group 2 - The tracking credit rating report for the convertible bonds can be found on the Shanghai Stock Exchange website [2]. - The announcement is made by the board of directors of Yifeng Pharmacy [3].

Group 1 - The issuer of the convertible bonds is Yifeng Pharmacy Chain Co., Ltd., with a total issuance amount of RMB 1,797.43 million, net proceeds after issuance costs amounting to RMB 1,780.26 million [2][3][14] - The bonds have a maturity period of six years, from March 4, 2024, to March 3, 2030, with a face value of RMB 100 per bond [3][4] - The coupon rates for the bonds are set at 0.30% for the first year, 0.50% for the second year, and 1.00% for the third year [4][5] Group 2 - The initial conversion price for the bonds is set at RMB 39.85 per share, subject to adjustments based on various corporate actions [5][6] - The conversion price will be adjusted to RMB 32.79 per share effective from June 7, 2024, due to the company's annual profit distribution [7][8] - Further adjustments will reduce the conversion price to RMB 32.54 per share effective from October 15, 2024, and to RMB 32.14 per share effective from June 18, 2025 [8][19] Group 3 - The total amount raised from the bond issuance will be used for projects including the construction of pharmaceutical warehouses in Jiangsu, Hubei, and Hebei, with a total investment of RMB 2,534.33 million [14][15] - The bonds are rated AA by a credit rating agency, with a stable outlook, and the issuer's credit rating is also maintained at AA [16][17] - The bonds will not be secured, and the management of the raised funds will be conducted in a designated special account [15][16] Group 4 - The actual controller and major shareholders have reduced their holdings of the convertible bonds, with a total of 5,259,730 bonds sold, representing 29.26% of the total issuance [20][21] - The company has also repurchased and canceled a portion of restricted stock from its 2022 incentive plan, which does not affect the conversion price of the bonds [21][22] - The company will continue to monitor the impact of these actions on its operational performance and debt repayment capabilities [22]

Core Viewpoint - Yifeng Pharmacy (603939) announced that Huxin Chuangtou, Yizhi Feng, and Yiren Tang plan to collectively reduce their holdings by no more than 2% of the company's shares [1] Group 1 - The total planned reduction in shareholding is capped at 2% [1]

Core Viewpoint - The company announced an adjustment to the conversion price of its convertible bonds due to the implementation of its 2024 annual equity distribution plan, resulting in a decrease from 32.54 CNY to 32.14 CNY per share [1][3]. Group 1: Bond Information - The convertible bond, referred to as "益丰转债," was publicly issued on March 4, 2024, and listed on the Shanghai Stock Exchange on March 27, 2024 [1]. - The bond has a maturity period of 6 years, from March 4, 2024, to March 3, 2030, with a conversion period from September 8, 2024, to March 3, 2030 [1]. Group 2: Equity Distribution Details - The company plans to distribute a cash dividend of 0.40 CNY per share (including tax) to all shareholders, with the record date set for June 17, 2025, and the ex-dividend date on June 18, 2025 [2]. - The adjustment to the conversion price is based on the company's equity distribution plan, which includes provisions for adjusting the conversion price in the event of cash dividends, stock dividends, or other equity changes [2]. Group 3: Conversion Price Adjustment - The conversion price adjustment formula is specified in the company's prospectus, detailing how the price will be recalculated based on various equity distribution scenarios [2]. - The adjusted conversion price of 32.14 CNY per share will take effect on June 18, 2025, following the equity distribution [3]. - The convertible bonds will be suspended from conversion from June 11, 2025, to June 17, 2025, and will resume conversion on June 18, 2025 [3].

Key Points - The company announced a cash dividend of 0.40 CNY per share for A shares [1][2] - The dividend distribution was approved at the annual shareholders' meeting on May 29, 2025 [1] - The total cash dividend to be distributed amounts to approximately 484.97 million CNY based on the total share capital of 1,212,416,854 shares [1][2] Relevant Dates - The record date for the dividend is June 17, 2025, with the ex-dividend date on June 18, 2025, and the payment date also on June 18, 2025 [2][3] Distribution Implementation - Cash dividends will be distributed through China Securities Depository and Clearing Corporation Limited, Shanghai Branch, to shareholders registered by the record date [2] - The distribution does not involve the issuance of bonus shares or capital increase [2] Taxation Information - For individual shareholders holding shares for over one year, the cash dividend is exempt from personal income tax, resulting in a net distribution of 0.40 CNY per share [3][4] - For shares held for less than one year, the tax rate varies based on the holding period, with a maximum effective tax rate of 20% for shares held for one month or less [3][4] - For Hong Kong investors, the net cash dividend after a 10% withholding tax will be 0.36 CNY per share [4]

Group 1 - The company held its fourth meeting of the fourth Supervisory Board, which was convened by the chairperson Meng Peng, with all three supervisors present, complying with relevant laws and regulations [1] - The Supervisory Board approved the proposal to conclude certain fundraising projects and permanently supplement working capital with the remaining funds, which is seen as a reasonable decision to enhance the efficiency of fund usage and beneficial for the company's long-term development [1][2] - The proposal regarding the cancellation of unvested restricted stock due to the departure of two incentive targets and the failure to meet performance targets for the 2024 fiscal year was discussed, resulting in a total of 1.63205 million shares being rendered invalid [2][3] Group 2 - The voting results for the proposal to conclude fundraising projects showed unanimous support with 3 votes in favor, while the proposal regarding the cancellation of restricted stock could not be resolved due to insufficient non-related supervisors present to form a quorum [2][3] - The company plans to disclose further details regarding the cancellation of restricted stock on the official information platform [2][3]

Group 1 - The annual shareholders' meeting of Yifeng Pharmacy Chain Co., Ltd. was held on May 29, 2025, in Changsha, Hunan Province [2] - The meeting was conducted in compliance with the Company Law and the company's articles of association, utilizing both on-site and online voting methods [2][3] - All current directors and supervisors attended the meeting, with a total of 9 directors and 3 supervisors present [3] Group 2 - All proposed resolutions were approved during the meeting, including the annual work reports of the board and supervisory committee, financial statements, and profit distribution plan for 2024 [4][5][6] - The meeting authorized the board to formulate a mid-term dividend plan and approved the appointment of an accounting firm for 2025 [5][6] - A significant resolution regarding the company's shareholder return plan for the next three years (2025-2027) was also passed [6] Group 3 - The meeting was witnessed by lawyers from Hunan Qiyuan Law Firm, confirming that the meeting's procedures and voting results were legally valid [6]

Core Viewpoint - The company, Yifeng Pharmacy Chain Co., Ltd., is set to hold an annual performance briefing for 2024 and the first quarter of 2025 on June 3, 2025, to provide insights into its operational results and financial status [2][3][4]. Group 1: Performance Briefing Details - The performance briefing will take place on June 3, 2025, from 15:00 to 16:00 [4]. - The event will be held at the Shanghai Stock Exchange Roadshow Center and will utilize video and online interaction for communication [4][5]. - Investors can submit questions for the briefing from May 27 to June 2, 2025, through the Roadshow Center website or via the company's email [2][5]. Group 2: Management Participation - Key participants in the briefing will include the Chairman and CEO, Mr. Gao Yi, the Financial Officer, Mr. Wang Yonghui, the Board Secretary, Mr. Fan Wei, and the Independent Director, Mr. Huang Chunan [4]. Group 3: Shareholding and Reduction Plan - Prior to the reduction plan, the Executive President, Mr. Gao Youcheng, held 201,600 shares, representing 0.0166% of the total share capital, while the Assistant President, Mr. Yan Jun, held 99,600 shares, representing 0.0082% [8]. - The reduction plan was disclosed on January 24, 2025, with a maximum reduction of 75,300 shares planned, which was successfully executed within the specified timeframe [9][10].